Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125618181 | 12561818 | 1 | I | 20160331 | 20160711 | 20160715 | 20160715 | EXP | FR-ELI_LILLY_AND_COMPANY-FR201607003103 | ELI LILLY AND CO | 80.57 | YR | F | Y | 71.40000 | KG | 20160714 | CN | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125618181 | 12561818 | 1 | PS | HUMALOG | INSULIN LISPRO | 1 | Unknown | UNK, UNKNOWN | U | U | 20563 | ||||||||
| 125618181 | 12561818 | 2 | SS | NEBIVOLOL. | NEBIVOLOL | 1 | Oral | 5 MG, QD | Y | U | 0 | 5 | MG | QD | |||||
| 125618181 | 12561818 | 3 | C | TRINITRINE | NITROGLYCERIN | 1 | Transdermal | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 125618181 | 12561818 | 4 | C | KARDEGIC | ASPIRIN LYSINE | 1 | Oral | 1 DF, QD | U | 0 | 1 | DF | POWDER FOR ORAL SOLUTION | QD | |||||
| 125618181 | 12561818 | 5 | C | KALEORID LP | POTASSIUM CHLORIDE | 1 | Oral | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 125618181 | 12561818 | 6 | C | GALVUS | VILDAGLIPTIN | 1 | Oral | 1 DF, QD | U | 0 | 1 | DF | TABLET | QD | |||||
| 125618181 | 12561818 | 7 | C | VALSARTAN. | VALSARTAN | 1 | Oral | 160 MG, QD | U | 0 | 160 | MG | QD | ||||||
| 125618181 | 12561818 | 8 | C | LASILIX SPECIAL /00032601/ | FUROSEMIDE | 1 | Oral | 125 MG, QD | U | 0 | 125 | MG | QD | ||||||
| 125618181 | 12561818 | 9 | C | EXELON | RIVASTIGMINE TARTRATE | 1 | Transdermal | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 125618181 | 12561818 | 10 | C | EBIXA | MEMANTINE HYDROCHLORIDE | 1 | Unknown | UNK, UNKNOWN | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125618181 | 12561818 | 1 | Diabetes mellitus |
| 125618181 | 12561818 | 2 | Product used for unknown indication |
| 125618181 | 12561818 | 3 | Product used for unknown indication |
| 125618181 | 12561818 | 4 | Platelet aggregation |
| 125618181 | 12561818 | 5 | Product used for unknown indication |
| 125618181 | 12561818 | 6 | Product used for unknown indication |
| 125618181 | 12561818 | 7 | Product used for unknown indication |
| 125618181 | 12561818 | 8 | Product used for unknown indication |
| 125618181 | 12561818 | 9 | Product used for unknown indication |
| 125618181 | 12561818 | 10 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125618181 | 12561818 | HO |
| 125618181 | 12561818 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125618181 | 12561818 | Hypoglycaemia | |
| 125618181 | 12561818 | Loss of consciousness | |
| 125618181 | 12561818 | Malaise |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125618181 | 12561818 | 2 | 20160401 | 0 |